Stockscreener 앱 받기
8.53
5.54%
-0.50
시간 외 거래:
8.53
전일 마감가:
$9.03
열려 있는:
$9.07
하루 거래량:
398.48K
Relative Volume:
1.71
시가총액:
$469.90M
수익:
$79.55M
순이익/손실:
$-37.25M
주가수익비율:
-12.09
EPS:
-0.7054
순현금흐름:
$-25.40M
1주 성능:
-4.48%
1개월 성능:
+1.31%
6개월 성능:
+142.33%
1년 성능:
+157.70%
1일 변동 폭
$8.49
$9.07
1주일 범위
$8.49
$9.7126
52주 변동 폭
$3.19
$9.7126
Sight Sciences Inc Stock (SGHT) Company Profile
명칭
Sight Sciences Inc
전화
(415) 889-0550
주소
4040 CAMPBELL AVE,, MENLO PARK
Compare SGHT vs ABT, MDT, SYK, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SGHT
Sight Sciences Inc
|
8.53 | 491.94M | 79.55M | -37.25M | -25.40M | -0.7054 |
ABT
Abbott Laboratories
|
97.50 | 175.27B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
86.38 | 113.38B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
275.43 | 104.47B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
42.60 | 63.65B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.15 | 49.74B | 6.30B | 1.07B | 1.09B | 1.8406 |
Sight Sciences Inc Stock (SGHT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-05 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2025-08-08 | 업그레이드 | Lake Street | Hold → Buy |
| 2024-12-06 | 개시 | UBS | Buy |
| 2024-11-04 | 다운그레이드 | Lake Street | Buy → Hold |
| 2024-08-21 | 개시 | Lake Street | Buy |
| 2023-09-12 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-09-12 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-09-12 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-08-24 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-07-10 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-01-06 | 업그레이드 | Stifel | Hold → Buy |
| 2022-10-04 | 개시 | Needham | Hold |
| 2022-07-26 | 개시 | Stifel | Hold |
| 2022-02-03 | 개시 | William Blair | Outperform |
| 2022-01-07 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
모두보기
Sight Sciences Inc 주식(SGHT)의 최신 뉴스
A proposed $268K share sale at Sight Sciences (SGHT) includes an amount to cover an equity-award tax bill. - Stock Titan
An officer proposes selling 7,797 Sight Sciences (SGHT) shares, including an amount to cover taxes. - Stock Titan
Sight Sciences, Inc. Announces Commercial Availability Of OMNI Ultra Surgical System And Previews Clearance Assistant Plus At AAO - marketscreener.com
Sight Sciences launches OMNI Ultra surgical system for glaucoma By Investing.com - Investing.com Canada
Sight Sciences to Debut the OMNI Ultra® Surgical System, - GlobeNewswire
Form 144 Sight Sciences For: 30 September By Investing.com - Investing.com Nigeria
Former officer Jeremy Hayden proposes selling 22,254 Sight Sciences (SGHT) shares. - Stock Titan
Sight Sciences stock gains as William Blair raises its rating - AD HOC NEWS
Sight Sciences stock holds steady as investors await next earnings update - AD HOC NEWS
SGHTSight Sciences Inc Volatility & Greeks - Finviz
Sight Sciences Inc (NASDAQ: SGHT) Share Price, SGHT Stock News, SGHT Share Price & Updates - Kalkine
Sight Sciences stock holds steady as investors watch recent ophthalmology results - AD HOC NEWS
Former Sight Sciences (SGHT) officer lines up more stock sales - Stock Titan
Sight Sciences stock holds steady as investors watch growth metrics - ad-hoc-news.de
Morgan Stanley healthcare talk featuring Sight Sciences will stream live Sept. 15 - Stock Titan
Former Sight Sciences (NASDAQ: SGHT) officer lines up more share sales after a string of summer trades - Stock Titan
Price to sales forward of Sight Sciences, Inc. – NASDAQ:SGHT - TradingView
Sight (SGHT) Q2 2026 Scorecard: EPS Beats Its Estimate at the Close; Share Move: Shares Close 1.45% Higher on the DayConsensus Beat Rate - careplusvn.com
FDA Broadens ‘Indications for Use’ for Sight Sciences’ TearCare System - VisionMonday.com
Sight Sciences Announces FDA Expanded Indication for TearCare to Improve Meibomian Gland Function in Evaporative Dry Eye Disease - Quiver Quantitative
TearCare Becomes the First and Only MGD Treatment Indicated - GlobeNewswire
GSA Capital Partners LLP Makes New Investment in Sight Sciences, Inc. $SGHT - MarketBeat
TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease - The Manila Times
FDA recalls over 39K bottles of CLEAR EYES Maximum Itchy Relief drops - Glance by Eyes On Eyecare
A Quick Look at Today's Ratings for Sight Sciences(SGHT.US), With a Forecast Between $8 to $12 - Moomoo
Sight Sciences Earnings Call Shows Growth And Discipline - TipRanks
Sight Sciences (NASDAQ: SGHT) holder to sell 12,014 shares - Stock Titan
Sight Sciences (SGHT) Pulls Back to $8.14: Range-Bound Move Tests Key Support ZoneVol Target Rebalance - vinanet.vn
Sight Sciences (SGHT) insider plans 48,000-share stock sale after option exercise - Stock Titan
SGHT (SGHT) holder files to sell 2,500 shares after stock vesting - Stock Titan
Sight Sciences (SGHT) Q2 2026 Earnings Call Transcript - AOL.com
SGHT insider Jeremy Hayden files Form 144 for recent and planned stock sales - Stock Titan
SGHT Q2 2026 Earnings: Narrowed Loss Beats Estimates, Shares Jump 6.49%Earnings Turnaround - Vinanet
SGHT (NASDAQ: SGHT) insider Jeremy Hayden plans $165,878 stock sale - Stock Titan
Sight Sciences appoints Kashif Rashid as chief legal officer, Jeremy Hayden to step down By Investing.com - Investing.com Australia
Sight Sciences Names Kashif Rashid as New Chief Legal Officer Amid Leadership Change - Kalkine Media
Sight Sciences names Kashif Rashid chief legal officer, replacing Jeremy Hayden - Bitget
Sight Sciences Appoints New Chief Legal Officer Rashid - tipranks.com
Sight Sciences appoints Kashif Rashid as chief legal officer, Jeremy Hayden to step down - Investing.com Nigeria
Form 8K Sight Sciences Inc For: 10 August By Investing.com - Investing.com Nigeria
Sight Sciences(SGHT) Stock Options Chain | Quotes & News - Moomoo
Sight Sciences Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance - 富途牛牛
Sight Sciences (NASDAQ:SGHT) Rating Increased to Buy at Wall Street Zen - MarketBeat
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE) and Sight Sciences (SGHT) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX), Revolution Medicines (RVMD) and Sight Sciences (SGHT) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Zimmer Biomet Holdings (ZBH), Cytek Biosciences (CTKB) and Sight Sciences (SGHT) - The Globe and Mail
UBS Group Forecasts Strong Price Appreciation for Sight Sciences (NASDAQ:SGHT) Stock - MarketBeat
UBS Adjusts Price Target on Sight Sciences to $8 From $7, Maintains Buy Rating - marketscreener.com
Sight Sciences, Inc. Stock 12‑Month Price Target Raised to $8.6, Implies 55% Upside - TradingView
Sight Sciences Reports Second Quarter 2026 Financial Results - The Manila Times
Sight Sciences Q2 Earnings Call Highlights - MarketBeat
Sight Sciences Inc (SGHT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.26%
0.38%
자본화:
|
볼륨(24시간):